Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-2129 tablet approved to conduct clinical trials for treating acute pain.
[Translation]
Hengrui Medicine (600276.SH) announced that recently, its subsidiary Shanghai Hengrui Medicine Co., Ltd. and Shandong Shengdi...
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiaries Shanghai Jiangsu Hengrui Pharmaceuticals Co., Ltd. and Shandong Shengdi Pharmaceutical Co., Ltd. have recently received the approval notice for drug clinical trial of HRS-2129 tablets from the National Medical Products Administration ("NMPA"). The approval allows the product to conduct clinical trials for the treatment of acute pain. According to the information available, there are currently no similar products approved for marketing both domestically and internationally.
Related Articles
UBOX ONLINE (02429) repurchased 76,500 shares for 175,400 Hong Kong dollars on June 17th.
ES SERVICES spent HK$348,200 to repurchase 200,000 shares on June 17, 01995.
TECHTRONIC IND(00669) issued 17,000 shares due to the exercise of stock options.
UBOX ONLINE (02429) repurchased 76,500 shares for 175,400 Hong Kong dollars on June 17th.
ES SERVICES spent HK$348,200 to repurchase 200,000 shares on June 17, 01995.
TECHTRONIC IND(00669) issued 17,000 shares due to the exercise of stock options.
RECOMMEND
